Form 4: Arcutis Biotherapeutics CFO David Topper Reports Acquisition of Stock and Stock Options

David Topper, CFO of Arcutis Biotherapeutics, reports the acquisition of 34,000 shares of common stock and options to purchase 89,000 shares.

Summary

• On February 28, 2025, David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported transactions involving the company's securities.
• Topper acquired 34,000 shares of common stock in the form of restricted stock units (RSUs) at a price of $0.
• These RSUs vest 25% annually beginning on March 1, 2026, contingent upon continued service to the Issuer.
• Topper also acquired options to purchase 89,000 shares of common stock at an exercise price of $13.69.
• These options vest monthly, with 1/48th of the shares vesting each month starting March 1, 2025, and will be fully vested by the fourth anniversary, also contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock and option grants to a company executive. The vesting schedules suggest a long-term commitment.

Positives

• The acquisition of stock and options by the CFO could be interpreted as a sign of confidence in the company's future performance.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Monitoring these transactions can provide insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of management's confidence.

Key Dates